NYU LANGONE HEALTH

Genascence's GNSC-001, a gene therapy for OA, received FDA Fast Track designation. GNSC-001 targets IL-1, a key mediator in OA pathogenesis, aiming for long-term inhibition with a single injection. Phase 1 data showed GNSC-001 was well-tolerated and improved pain and function scores.

NYU Langone Health presents findings on valacyclovir's effectiveness in zoster eye disease, Ozempic's pain reduction in knee osteoarthritis, Halloween mask safety, first U.S. cases of sexually transmitted ringworm, increased family meals during the pandemic, and more, highlighting various medical advancements and expert insights.

Ataraxis AI emerges with $4M seed funding, unveiling Ataraxis Breast, a 30% more accurate AI-native breast cancer test. The company aims to develop AI-powered diagnostic tests for 50% of 2030's expected 26M cancer patients, transforming cancer care with personalized treatments.

Ataraxis AI launches with $4M seed funding, unveiling Ataraxis Breast, a 30% more accurate AI-native breast cancer diagnostic. Yann LeCun serves as AI advisor.

Becker's honors healthcare CNOs for tackling nurse staffing shortages, managing budgets, and developing professional growth opportunities. CNOs oversee nursing departments, spearhead innovative patient care initiatives, and bring clinical expertise and executive leadership skills. The list is based on nominations and editorial research, with leaders presented in alphabetical order.

Elisabeth Cohen, a former cornea specialist, experienced shingles in 2008, leading to vision loss in her right eye. She initiated the ZEDS trial, a $15 million study across 95 centers, which found that low-dose valacyclovir reduced the risk of new or worsening eye disease by 26% after a year. Cohen's work highlights the need for better awareness and use of the shingles vaccine, which can significantly lower the risk of dementia.

FDA approved Vorasidenib, an IDH inhibitor, for treating IDH mutant gliomas, showing a 27-month delay in tumor progression and fewer side effects compared to standard treatments.

Gliomas, common brain tumors in adults, often have IDH gene mutations. Molecular testing identifies these mutations, enabling targeted treatments like IDH inhibitors, improving patient outcomes. Testing is crucial for personalized treatment and is covered by insurance.